INTRODUCTION {#S1}
============

Drug allergy is an immunologically mediated response to specific agent in a sensitized person.[@B1] The clinical manifestations of drug allergy are restricted to certain syndromes that are specifically accepted as allergic in nature, which may present as mild to life-threatening reactions.[@B2] The estimated incidence of drug allergy was 0.018-4.2 per 1000 hospitalizations[@B3],[@B4], and the estimated mortality related to drug allergy was 0.09 per 1000 hospitalizations (95%CI 0.06, 0.12).[@B4]

In Thailand, the occurrence of anaphylaxis in a university hospital increased from 9.16 per 100,000 admitted persons in 1999 to 55.45 per 100,000 admitted persons in 2004, in which 50.0% of identifiable causes were drugs.[@B5] Practices in the Thai healthcare system could potentially contribute to recurrent drug allergy because patients can obtain medications from pharmacies without prescriptions, and there is inadequate documentation and communication regarding drug allergy between health providers.[@B6],[@B7] In addition, medication names are presented in English, and available medication information leaflets are not commonly designed for patient use, being targeted at healthcare professionals. Hence it can be difficult for patients with poor health literacy to recall medication names and understand printed information.[@B8]

While a clear and standardized form is important for documentation of drug allergy[@B9],[@B10], empowering both public and healthcare professionals is also necessary for more complete drug allergy documentation.[@B11] The Thai Ministry of Public Health has mandated that drug allergy cards should be provided to patients experiencing serious Adverse Drug Reactions (ADRs) or ADRs which are intolerable or reduce quality of life to prevent future exposure to these drugs. While cards can be useful, their effectiveness in preventing future recurrence depends on patients' knowledge and understanding of drug allergy. Patients need to carry their drug allergy cards and show them to healthcare professionals at the point of prescribing. Small studies suggest that pharmacists providing counseling to patients about drug allergy and providing basic information about ADRs and their management, together with written information, could result in improved knowledge.[@B12],[@B13] Neither of these studies assessed whether pharmacist counseling was more effective than written information alone or assessed behaviours related to drug allergy. This study, therefore, aimed to evaluate the effectiveness of management in improving knowledge and understanding about drug allergy and behavior-related to drug allergy cards in patients with a history of drug allergy.

METHODS {#S2}
=======

The study was approved by the Khon Kaen University Ethics Committee for Human Research (Institutional Review Board Number: IRB00001189), and conducted at Srinagarind Hospital, an 800-bed university teaching hospital in northeast Thailand. This was a before-and-after study investigating management that involved providing different designs of educational brochures and the addition of pharmacist counseling to a brochure, in order to improve knowledge and understanding about drug allergy and behavior-related to drug allergy card.

Development of educational brochures {#S3}
------------------------------------

Two newly designed brochures, Brochure A and Brochure B, were specially developed for this study and used to educate patients about drug allergy and the importance of drug allergy cards. Both brochures contained similar information explaining about the definitions of drug allergy and side effects, basic observation of drug allergy symptoms, self-management of drug allergy, and how to prevent recurrence. However, the colors used, and information and illustrations of drug allergy differed between brochures. Brochure A used fair color (light-green) as a background and presented information and illustrations of common drug allergy symptoms, for example, maculopapular rash and urticaria. Brochure B used gaudy color (crimson) as a background and presented information and illustration of serious drug allergy symptoms, for example, anaphylactic shock and Stevens-Johnson syndrome. Content was adapted from publications and electronic sources. A dermatologist and a hospital pharmacist, responsible for ADR monitoring, evaluated the clarity, meaningfulness, appropriateness of wording and the format of the brochures. Following this, the brochures were distributed to 20 outpatients to investigate their understanding of the information provided and their preference on brochure design. Patients' comments were then used to revise the final versions of the two brochures used in the study.

Questionnaire Development {#S4}
-------------------------

The questionnaire was initially developed using an adapted drug hypersensitivity questionnaire developed by the European Network for Drug Allergy (ENDA) and a model for understanding patient attribution of ADRs.[@B14],[@B15] Content validity of the questionnaire was tested by four experts, two internal medicine doctors and two hospital pharmacists, and calculated for Index of Consistency (IOC). The 'think aloud' technique, requiring patients to explain how they think or perceive while completing the questionnaires, was performed in five outpatients who had received drug allergy cards at the pharmacy department to assess ease of use and understanding. Comments and suggestions were used to revise the final questionnaire to ensure its appropriateness. Test-retest reliability was then conducted with fifteen eligible patients by completing two copies of the questionnaire two weeks apart.

This paper-based questionnaire consisted of three sections including demographic data and clinical data (7 questions), questions assessing knowledge and understanding of drug allergy and drug allergy cards (5 questions), and questions assessing behavior-related to drug allergy card (2 questions). There were five domains for evaluating patients' knowledge and understanding of drug allergy. Each domain resulted in a score of one, giving a maximum score of five. To attain the maximum score, respondents were required to: (i)provide the full name of the drug to which they were allergic(ii)provide at least one drug allergy symptom(iii)select one or two correct options from six statements relating to management of drug allergy(iv)provide all correct responses to four "Yes/ No" statements concerning prevention of recurrent drug allergy(v)provide all correct responses to five "Yes/ No" statements concerning the purpose of the drug allergy card.

The total score was then dichotomized to provide two levels of knowledge and understanding: low to average (score 0 to 3) and good (score 4 or 5).

Patients had to read and completed the questionnaires by themselves, however, for those who had literacy difficulties, care givers were allowed to carry out these procedures according to patients' responses.

Main study procedures {#S5}
---------------------

The study involved 1,085 patients participating in two consecutive study phases: Phase 1 recruited patients for self-education (Group 1), who received the brochure only; Phase 2 recruited patients to a pharmacist-counseled group (Group 2), who received the brochure plus pharmacist counseling.

Phase 1: the subjects were 985 patients who had previously been recorded as having a history of drug allergy identified from the pharmacy database or who were recorded with maculopapular rash, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis in their medical records. Baseline questionnaires were mailed to these patients. Brochures and follow-up questionnaires were then mailed to patients who returned a completed questionnaire one month later. Each patient received only one brochure, which were randomly allocated by simple random sampling method using table of random digits, therefore enabling the effectiveness of different brochure designs to be tested (Brochure A=149 patients and Brochure B=150 patients). Replacement drug allergy cards were provided to patients who indicated they did not have one in their baseline questionnaire response. Both questionnaires were returned to the researcher by mail. This study enabled selection of the most effective brochure for the Phase 2 study. It was conducted between May 1 and July 31, 2009.

Phase 2: subjects were recruited prospectively during a three month period from in-patients who experienced a drug allergy during current hospitalization or were admitted as a result of a drug allergy or out-patients who were screened positively by pharmacists for previous drug allergy during prescription dispensing (Group 2). All patients received baseline questionnaires directly from a pharmacist and this was returned to the pharmacist directly after completion. After completing the baseline questionnaire, a pharmacist reinforced the information about drug allergy that was contained in the brochure, and also: used a standardized diagram to counsel patients about mechanisms, prognosis and complications of drug allergy; emphasized the need to remember the name of the allergic drug and other drugs that could possibly cause the same allergic reactions; advised patients to tell their close family about this drug allergy; and suggested how replacement drug allergy cards could be obtained. This counseling was performed at the outpatient pharmacy department or at inpatient wards depending on the recruitment site and took approximately 15-20 minutes. Drug allergy cards were also provided to patients whose questionnaire responses indicated they did not have one. Follow-up questionnaires were immediately delivered to patients at the study site and they were returned by mail one month after the intervention. This phase was conducted between August 1 and October 10, 2009.

Patients, who did not return the questionnaires within three-week period after sending mails, received telephone and/or postcard reminders twice at three and six weeks. A flowchart of the overall study procedures is shown in [Figure 1](#F1){ref-type="fig"}.

![Flowchart of the overall study procedure](pharmpract-13-513-g001){#F1}

Data Analysis {#S6}
-------------

The data were analyzed using SPSS version 19.0. Relationships between variables were analyzed using Pearson chi-square test or Fisher's exact test where appropriate. The 95% confidence interval or p-value at 0.05 was chosen to accept or reject the null hypothesis.

Independent t-test or Mann-Whitney U test were used to compare pre-and post-test mean total scores between two groups of patients, while Paired t-test or Wilcoxon Signed-rank test were used to compare mean total scores between pre-and post-intervention. McNemar's test was used for comparing individual knowledge questions and behaviours at baseline and one month later in both groups.

Stepwise logistic regression was used to test for independent variables identified by univariate analyses as being associated with level of knowledge and understanding assessed at baseline using combined data from Group 1 (299 patients) and Group 2 (100 patients).

RESULTS {#S7}
=======

Questionnaire development {#S8}
-------------------------

The Index of Consistency (IOC) of the questionnaires was 0.88, which meant that all questions were related to objectives of the study. The Pearson's correlation coefficient was analyzed for test-retest reliability in 'knowledge and understanding of drug allergy and drug allergy card' section, in which the coefficient was 0.75.

Response rate {#S9}
-------------

Group 1: At baseline, 382 questionnaires were returned (response rate 38.8%), of which 299 were fully completed. The complete follow-up questionnaires were returned from 179 respondents (59.9%) who had received Brochure A (89 patients) and Brochure B (90 patients).

Group 2: All 100 baseline questionnaires were returned and the response rate of follow-up questionnaires was 96.0%.

Brochure selection {#S10}
------------------

There were no differences in the demographic characteristics of gender, age, education, total number of drugs used, number of drug allergies, and drug allergy card availability between patients who received the different brochures. Knowledge and behaviors in relation to drug allergy and drug allergy cards between these two sub-groups were not significantly different \[all P\>0.05) both at baseline (mean total scores Brochure A=3.21 (SD=1.07) and Brochure B=3.33 (SD=1.00)\] and follow-up \[Brochure A=3.46 (SD=1.04) and Brochure B=3.52 (SD=0.77)\]. Patients receiving both Brochures showed significant improvements in mean total score after receiving the intervention (all P\<0.05). The frequency of self-reported presenting and carrying drug allergy cards was slightly lower after the intervention, but this was not statistically significant ([Table 1](#T1){ref-type="table"}). Both brochures were thus able to be used for the Phase 2 study.

###### 

Baseline and follow-up scores for knowledge and understanding of drug allergy and related-behaviors between different brochures in Phase 1 study

  Outcome measurement                  Brochure A, n (%) (N=89)   Brochure B, n (%) (N=90)   Difference                                                                                                                                  
  ------------------------------------ -------------------------- -------------------------- --------------------------------------- ----------- ----------- --------------------------------------- ----------------------------------- ---------------------------------------
  Knowledge                                                                                                                                                                                                                              
  Correct drug name                    55 (61.8)                  59 (66.3)                  \>0.05^[a](#t1n1){ref-type="fn"}^       57 (63.3)   65 (72.2)   \<0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}
  Symptoms identified                  68 (76.4)                  70 (78.7)                  \>0.05[^a^](#t1n1){ref-type="fn"}       77 (85.6)   76 (84.4)   \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}
  Correct management                   82 (92.1)                  79 (88.8)                  \>0.05[^a^](#t1n1){ref-type="fn"}       76 (84.4)   84 (93.3)   \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}
  Correct recurrence prevention        71 (83.5)                  80 (89.9)                  \>0.05[^a^](#t1n1){ref-type="fn"}       76 (88.4)   83 (92.2)   \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}
  Correct purpose of allergy card      12 (13.8)                  19 (21.3)                  **\<0.05[^a^](#t1n1){ref-type="fn"}**   15 (17.2)   9 (10.1)    \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   **\<0.05[^c^](#t1n3){ref-type="fn"}**
  Total knowledge score                3.21±1.07                  3.46±1.04                  **\<0.01[^b^](#t1n2){ref-type="fn"}**   3.33±1.00   3.52±0.77   **\<0.05[^b^](#t1n2){ref-type="fn"}**   \>0.05[^d^](#t1n4){ref-type="fn"}   \>0.05[^d^](#t1n4){ref-type="fn"}
  Behavior[\*](#t1n5){ref-type="fn"}                                                                                                                                                                                                     
  Always carry card                    54 (87.1)                  49 (79.0)                  \>0.05[^a^](#t1n1){ref-type="fn"}       49 (79.0)   50 (80.6)   \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}
  Always present card                  42 (66.7)                  41 (65.1)                  \>0.05[^a^](#t1n1){ref-type="fn"}       53 (79.1)   54 (80.6)   \>0.05[^a^](#t1n1){ref-type="fn"}       \>0.05[^c^](#t1n3){ref-type="fn"}   \>0.05[^c^](#t1n3){ref-type="fn"}

Comparing between Baseline and Follow-up within group used McNemar test

Comparing between Baseline and Follow-up within group used Wilcoxon Signed Ranks Test

Comparing between Groups at baseline and at follow-up used Pearson Chi-square test

Comparing between Group at baseline and at follow-up used Mann Whitney U test

Total respondents who completed both questionnaires at baseline and follow-up: Brochure A- Carry card (n=62) and Present card (n=63); Brochure B- Carry card (n=62) and Present card (n=67)

Comparing between Managements {#S11}
-----------------------------

### Patient characteristics {#S12}

The general characteristics of patients in Group 1 and Group 2 patients were similar. The majority were female (59.6%) with a high proportion being aged between 41-60 years old (45.5%), the mean age being 48.41 (SD=17.29) years. The most common educational level was secondary school or lower (63.8%) and the majority had a total income less than 10,000 Baht per month (60.5%). However, patients in Group 1 had more drug allergies than those in Group 2 and were more likely to indicate they possessed a drug allergy card. ([Table 2](#T2){ref-type="table"})

###### 

Patient characteristics between groups of patients

  Characteristics                    No. of Patients (%)   p-value                     
  ---------------------------------- --------------------- ------------- ------------- ------------
  Gender                                                                               0.847^a^
  Female                             106 (59.2)            58 (60.4)     164 (59.6)    
  Male                               73 (40.8)             38 (39.6)     111 (40.4)    
  Total                              179 (100.0)           96 (100.0)    275 (100.0)   
  Age (years)                                                                          0.369^a^
  \< 20                              17 (9.5)              4 (4.2)       21 (7.6)      
  21-40                              38 (21.2)             21 (21.9)     59 (21.5)     
  41-60                              82 (45.8)             43 (44.8)     125 (45.5)    
  \> 60                              42 (23.5)             28 (29.2)     70 (25.5)     
  Total                              179 (100.0)           96 (100.0)    275 (100.0)   
  Mean ± S.D.                        47.67±17.74           49.78±16.42   48.41±17.29   0.335^b^
  Median ± IQR                       51±21                 50.5±24       51±23         0.514^c^
  Educational Level                                                                    
  Primary school or lower            65 (36.3)             34 (36.2)     99 (36.3)     0.999^a^
  Secondary school                   49 (27.4)             26 (27.7)     75 (27.5)     
  Bachelor degree or higher          65 (36.3)             34 (36.2)     99 (36.2)     
  Total                              179 (100.0)           94 (100.0)    94 (100.0)    
  Income (Baht/ month)                                                                 0.870^a^
  Less than 10,000                   104 (60.1)            52 (61.2)     156 (60.5)    
  10,000 and higher                  69 (39.9)             33 (38.8)     102 (39.5)    
  Total                              173 (100.0)           85 (100.0)    258 (100.0)   
  Number of total drug use (items)                                                     0.454^a^
  0                                  59 (33.0)             33 (34.4)     92 (33.5)     
  1-2                                53 (29.6)             25 (26.0)     78 (28.4)     
  3-4                                40 (22.3)             17 (17.7)     57 (20.7)     
  5 or more                          27 (15.1)             21 (21.9)     48 (17.5)     
  Total                              179 (100.0)           96 (100.0)    275 (100.0)   
  Mean ± S.D.                        2.15±2.21             2.34±2.51     2.22±2.32     0.511^b^
  Median ± IQR                       2±3                   2±4           2±4           0.772^c^
  Number of drug allergy (Items)                                                       0.026^d^
  Cannot remember                    26 (15.1)             6 (6.3)       32 (12.0)     
  1                                  95 (55.2)             69 (72.6)     164 (61.4)    
  2-3                                46 (26.7)             19 (20.0)     65 (24.3)     
  4 or more                          5 (2.9)               1 (1.1)       6 (2.2)       
  Total                              172 (100.0)           95 (100.0)    267 (100.0)   
  Mean ± S.D.                        1.35±0.89             1.35± 0.78    1.35±0.85     
  Median (range)                     1 (6)                 1 (4)         1 (6)         
  Drug allergy card availability                                                       \<0.001^d^
  No                                 41 (22.9)             66 (70.2)     107 (39.2)    
  Yes                                132 (73.7)            27 (28.7)     159 (58.2)    
  Used to have                       6 (3.4)               1 (1.1)       7 (2.6)       
  Total                              179 (100.0)           94 (100.0)    273 (100.0)   

^a^Chi-square test, "Independent t-test, ^c^Mann-Whitney U test, ^d^Fisher's exact test

S.D. = Standard deviation, IQR= Interquartile range

### Knowledge and Understanding of Drug Allergy {#S13}

At baseline, the mean total score for drug allergy knowledge and understanding between both groups was not significantly different \[Group 1=3.27 (SD=1.03), Group 2=3.54 (SD=0.72); p=0.05\]. More than 60% of patients in both groups could report the names of the drugs to which they were allergic at baseline, with a higher proportion of those in Group 2 able to do so ([Table 3](#T3){ref-type="table"}). Penicillins were the most commonly implicated drugs (25.6%), followed by sulfonamides (10.5%) and tetracycline (5.0%). Most patients in both groups were also able to correctly report symptoms of their drug allergy and again more Group 2 patients were able to provide this information. Skin rash was the most frequently reported symptom (27.5%). The majority of patients in both groups selected one of the correct options for managing drug allergy and responded correctly to statements about preventing recurrence, but failed to correctly identify all statements relating to the purpose of the drug allergy card. The majority of respondents in both groups incorrectly gave a positive response to the statement "It could reduce the visit time at healthcare service" (Group 1: 53.4% and Group 2: 76.0%) and "Apart from the recorded drug on the drug allergy card, it prevents allergic reaction to other drugs" (Group 1: 76.1% and Group 2: 86.0%) ([Table 3](#T3){ref-type="table"}).

###### 

Baseline and follow-up scores for knowledge and understanding of drug allergy and related behaviors between groups of patients

  **Outcome measurement**              **Group 1, n (%) (N=179)**   **Group 2, n (%) (N=96)**   **Difference**                                                                                                                       
  ------------------------------------ ---------------------------- --------------------------- ----------------------------------- ----------- ------------ ----------------------------------- ----------------------------------- -----------------------------------
  Knowledge                                                                                                                                                                                                                          
  Correct drug name                    112 (62.6)                   124 (69.3)                  \>0.05[^a^](#t3n1){ref-type="fn"}   77 (80.2)   90 (93.8)    \<0.01[^a^](#t3n1){ref-type="fn"}   \<0.05[^c^](#t3n3){ref-type="fn"}   \<0.01[^c^](#t3n3){ref-type="fn"}
  Symptoms identified                  150 (83.8)                   146 (81.6)                  \>0.05[^a^](#t3n1){ref-type="fn"}   95 (99.0)   95 (99.0)    \>0.05[^a^](#t3n1){ref-type="fn"}   \<0.01[^c^](#t3n3){ref-type="fn"}   \<0.01[^c^](#t3n3){ref-type="fn"}
  Correct management                   157 (87.7)                   163 (91.1)                  \>0.05[^a^](#t3n1){ref-type="fn"}   92 (95.8)   91 (94.8)    \>0.05[^a^](#t3n1){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}
  Correct recurrence prevention        150 (83.8)                   163 (91.1)                  \>0.05[^a^](#t3n1){ref-type="fn"}   86 (89.6)   91 (94.8)    \<0.05[^a^](#t3n1){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}
  Correct purpose of allergy card      21 (12.1)                    28 (15.7)                   \>0.05[^a^](#t3n1){ref-type="fn"}   5 (5.2)     12 (12.6)    \>0.05[^a^](#t3n1){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}
  Total knowledge score                3.27±1.03                    3.49±0.91                   \<0.01[^b^](#t3n2){ref-type="fn"}   3.54±0.72   3.93±0.57    \<0.01[^b^](#t3n2){ref-type="fn"}   =0.05[^d^](#t3n4){ref-type="fn"}    \<0.01[^d^](#t3n4){ref-type="fn"}
  Behavior[\*](#t3n5){ref-type="fn"}                                                                                                                                                                                                 
  Always carry card                    101 (81.4)                   99 (79.8)                   \>0.05[^a^](#t3n1){ref-type="fn"}   23 (82.1)   26 (92.8)    \>0.05[^a^](#t3n1){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}   \<0.05[^c^](#t3n3){ref-type="fn"}
  Always present card                  95 (73.1)                    95 (73.1)                   \>0.05[^a^](#t3n1){ref-type="fn"}   24 (85.7)   28 (100.0)   \>0.05[^a^](#t3n1){ref-type="fn"}   \>0.05[^c^](#t3n3){ref-type="fn"}   \<0.01[^c^](#t3n3){ref-type="fn"}

Comparing between Baseline and Follow-up within group used McNemar test

Comparing between Baseline and Follow-up within group used Wilcoxon Signed Ranks Test

Comparing between Groups at baseline and at follow-up used Pearson Chi-square test

Comparing between Group at baseline and at follow-up used Mann Whitney U test

Total respondents who completed both questionnaires at baseline and follow-up: Group 1- Carry card (N=124) and Present card (N=130); Group 2- Carry card (N=28) and Present card (N=28)

After the intervention, both groups of patients were likely to have higher accuracy in almost every area of knowledge and understanding, however, significant differences were only seen in Group 2 patients in their ability to correctly name the drug to which they were allergic and to correctly identify statements on recurrence prevention (P\<0.01 and P\<0.05, respectively). The purpose of the drug allergy cards remained as the single most common area where patients' knowledge and understanding of drug allergy was lacking, having shown only marginal increases. The total scores at follow-up in both groups were significantly increased from baseline scores (P\<0.01; both groups). Group 2 patients however had significantly higher up total scores at follow-up than Group 1 patients ([Table 3](#T3){ref-type="table"}).

### Behaviors Concerning Drug allergy Cards {#S14}

Over 80% of patients in both groups at baseline claimed to always carry their drug allergy cards. After the intervention, there was a greater improvement seen in self-reported card carrying behavior in Group 2 compared to Group 1 (92.8% vs. 79.8%; P\<0.05). Most patients also claimed they always showed their drug allergy cards or notified staff about their drug allergies when presenting at healthcare services, again with no differences between groups at baseline. After the intervention, Group 2 patients reported higher frequency of self-reported presentation of their drug allergy cards when compared with Group 1 patients (100% vs. 73.1%; P\<0.01) ([Table 3](#T3){ref-type="table"}).

Patients who had two or more drug allergies were significantly more likely to report carrying drug allergy cards than those who had an allergy to only one drug (OR=3.218; 95%CI: 1.139 - 9.091; P=0.027).

Factors Affecting Knowledge and Understanding {#S15}
---------------------------------------------

Univariate analysis of all baseline questionnaire responses found that educational level (P\<0.001), income (P=0.001), and the availability of a drug allergy card (P=0.021) were significantly associated with good drug allergy knowledge. After adjusting for the independent factors by multivariate analysis, patients who had good baseline scores for knowledge and understanding were those who had graduated from secondary school or higher education (OR=1.913; 95%CI: 1.165 - 3.141; P=0.01), and patients who possessed a drug allergy card (OR=2.102; 95%CI: 1.334 - 3.311; P=0.001) ([Table 4](#T4){ref-type="table"}).

###### 

Factors associated with knowledge and understanding of drug allergy and drug allergy card of the patients \[Logistic Regression analysis: No. of patients = 372 cases\]

  Variables                           Crude OR^a^   95% CI^c^     Adjusted OR^b^   95% CI^c^     p- value
  ----------------------------------- ------------- ------------- ---------------- ------------- ----------
  Educational level                                                                              0.010
  Primary school and lower            1                           1                              
  Secondary school and higher         1.635         1.075-2.487   1.913            1.165-3.141   
  Income (Baht per month)                                                                        0.074
  \<10000                             1                           1                              
  10000 or more                       2.086         1.355-3.213   1.581            0.957-2.612   
  Availability of Drug Allergy Card                                                              0.001
  No                                  1                           1                              
  Ever had                            2.238         1.479-3.388   2.102            1.334-3.311   

^a^Crude Odd Ratio; ^b^Adjusted Odd Ratio \[Adjusted for educational level, income, and availability of drug allergy card\]; ^c^95% Confidence Interval,

DISCUSSION {#S16}
==========

The use of educational brochures containing illustrations of serious drug allergies on gaudy-color background or illustrations of non-serious drug allergies on light-color background were equally effective in improving patients' knowledge and understanding of drug allergy. In addition, pharmacist counseling plus the brochure was found to be more effective than brochure alone in promoting patients' knowledge and understanding of drug allergies, self-reported card-carrying and presenting cards to health professionals. Therefore, our results suggest that the effort involved in providing important information for patients and also in ensure it is explained is potentially valuable.

The majority of patients (88.2%) in our study were aware that they had experienced allergic reactions to at least one drug. This was a higher rate than that in other studies (17.2%-30.0%)[@B16],[@B17],[@B18] because our study recruited only patients with a clear history of drug allergy. The finding that 67.7% of all patients were able to name the allergic drugs was also slightly higher than found in a previous study (60.0%).[@B13] Inability to recall drug names could be due to long time intervals since experiencing the allergic reaction in some patients or failure to realize that the drug had caused the allergic reaction[@B19], but could also be due to English drug names being used.

Both interventions, self-education through provision of a brochure alone and pharmacist counseling plus brochure, resulted in a significant increase in knowledge scores, however, a greater improvement in behaviors regarding always carrying and presenting drug allergy cards was found in patients who received pharmacist counseling plus brochure than those who received brochure alone. In addition, higher educational level and owning a drug allergy card were significantly associated with greater knowledge and understanding, which is in line with previous work showing a positive correlation between educational level and knowledge of drug allergy.[@B13] The brochure intervention alone only impacted on overall knowledge score, not on self-reported behaviors. However, the patients in this study self-reported a higher frequency of carrying drug allergy cards than was found in other studies.[@B18],[@B20] Educational materials (e.g. brochures, charts) have previously been found to increase patients' knowledge and understanding of drug allergy, to encourage them in reporting drug allergy history, and discussing their drug-related problems with healthcare professionals.[@B13] The availability of drug allergy cards or bracelets which contain drug names and their allergic symptoms, do help patients to remember and prevent future exposure to the allergic drugs especially when patients are unable to communicate.[@B12] Pharmacists could encourage patients to always carry and present their drug allergy cards during routine service, while intensive counseling at the first exposure of drug allergy may provide better understanding in allergic drugs and other drugs with similar pharmacologic activity, mechanisms of drug allergy, and characteristics of allergic reactions to patients and family members, enabling greater understanding to prevent further occurrences.[@B12],[@B13] Our study suggests that educational brochures should be provided for all drug allergy patients to promote knowledge and understanding of drug allergy, whereas pharmacist counseling should focus on patients with poor knowledge and behaviors related to drug allergy.

There were a number of limitations in the present study. Firstly, the questionnaire required patients to retrospectively complete information about their history of drug allergy. Therefore, especially in Group 1 patients who were recruited from the records on hospital database, might have had difficulties in recalling their allergic experiences. Despite the reminding by telephone and/or postcards were undertaken, recall bias may discourage patients to return mailed questionnaires and have contributed to the low response rate of baseline questionnaires in Phase 1 study (38.8%). Nonetheless, this was similar to the response rate of mailed questionnaires in a previous study involving Thai patients (42.0%).[@B20] This may have resulted in a biased sample, with higher interest and thus knowledge of drug allergy. Secondly, some

information required for questionnaire validation, especially physical examinations, may have been recorded incompletely on patients' medical profiles, making assessment of the accuracy of patients' reports difficult. Thirdly, patients were derived from different populations and were not randomly allocated to groups. Nonetheless, characteristics of patients in both groups did not differ significantly in all key measures with the exception of the availability of drug allergy cards. Finally, although it was instructed that Group 1 patients must read brochure before completing the follow-up questionnaire, their actual compliance in doing so could not be assessed and the observed improvement in mean total knowledge score could not with certainty be as a result of receiving the brochure.

Prospective studies of longer duration should be performed to assess the long term efficacy of both these and other interventions in improving patients' knowledge, actual behaviors and allergy recurrence rate. In addition, future studies should investigate the cost-effectiveness of brochures in the prevention of recurrent drug allergy and patients' attitudes towards both brochures and counseling by pharmacists.

CONCLUSIONS {#S17}
===========

Pharmacist counseling with brochures was found to be more effective than brochures alone for improving patients' knowledge and understanding of drug allergies and drug allergy cards and in promoting drug allergy card carrying behavior. These techniques could be valuable in helping to reduce incidence of recurrent drug allergy.
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